Professor LAU Chak Sing

Porf CS Lau

Dean of Medicine
Daniel C K Yu Professorship in Rheumatology and Clinical Immunology
Chair of Rheumatology and Clinical Immunology

  • MBChB MD (Hons) FRCP (Edin, Glasg, Lond) FHKCP FHKAM (Medicine)
Personal Profile
Professor Chak-sing Lau is currently the Dean of the Li Ka Shing Faculty of Medicine. He is the immediate past Chairman of the Board of the Li Ka Shing Faculty of Medicine and Chairperson of the Department of Medicine, School of Clinical Medicine, the University of Hong Kong, and also the Chief of Service of the Queen Mary Hospital Department of Medicine.

Professor Lau graduated MBChB from the University of Dundee in 1985. In 1992, he joined the University of Hong Kong (HKU) as Lecturer in Medicine and successfully rose through the ranks to Senior Lecturer in 1997 and Professor in 2000. He returned to his Alma Mater in 2007 to become the first Chair of Rheumatology of the College of Medicine, Dentistry and Nursing Studies. In 2010, however, he began his second tenure at HKU as Chair Professor and later (2014) Daniel CK Yu Professor in Rheumatology and Clinical Immunology.

Within HKU Medicine, Professor Lau was Assistant Dean in Information Technology and Planning (2001-2004), Assistant Dean in Education and Student Affairs (2005-2007), Director of the Bau Institute of Medical and Health Sciences Education (2010-2018) and Associate Dean for Teaching & Learning (2013-2018). In 2016, he co-led the reform of the MBBS Curriculum incorporating a one-year enrichment experience for all medical students.

Professor Lau has been a major player in rheumatology in Hong Kong and beyond. Locally, he was President of the Hong Kong Society of Rheumatology (1997-2001) and Chairman of the Hong Kong College of Physicians Subspecialty Board in Rheumatology, Immunology & Allergy (2001-2007). In 2001, he founded the Hong Kong Arthritis & Rheumatism Foundation, the first and only local charity organisation that raises funds to support the psychosocial and therapeutic needs of patients with rheumatic diseases. Regionally, Professor Lau co-founded the Asian Congress on Autoimmunity, Huaxia Congress on the Management of Rheumatic Diseases and Ten Topics in Rheumatology in Asia. Notably, he was President of the Asia Pacific League of Rheumatology Associations (APLAR) between 2006-2008. In addition, Professor Lau led the development of the Region’s first treatment recommendations for rheumatoid arthritis and axial spondyloarthritis. In 2011, he co-founded the multi-national, multi-centre Asia Pacific Lupus Collaboration. Beyond the Asia Pacific region, Professor Lau was a member of the Outcome Measures in Rheumatology - OMERACT (1999-2002), European Alliance of Associations for Rheumatology (EULAR) Task Force on Rheumatoid Arthritis Treatment Recommendations (2019) and EULAR Scientific Committee (since 2019). Further, he was selected as an Honorary Member of EULAR in 2022.

Between 2016-2020, Professor Lau was President of the Hong Kong Academy of Medicine, having served as Vice-President (Education and Examinations) in the previous 5 years. He was a member of the COVID-19 Expert Advisory Panel for the Hong Kong Government of the SAR and sits on numerous strategic committees and working groups of the Food and Health Bureau, Hospital Authority, Department of Health and the Medical Council of Hong Kong. In January 2023, Professor Lau was appointed as a Member of the 14th National Committee of the Chinese People’s Political Consultative Conference (CPPCC) representing the health sector, and a general Member of the 14th Beijing Municipal Committee of the CPPCC on a 5-year term.


Research Profile
  • Mechanistic studies of cellular immune-dysregulation in systemic lupus erythematosus
  • Treatment and outcome studies in major autoimmune disorders including rheumatoid arthritis, systemic lupus erythematosus and spondyloarthritis

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease that affects predominantly young females and is associated with high morbidity and mortality. Immunologically, SLE is characterised by a loss of tolerance to self-antigens, T and B cell activation, and increased autoantibody production. Immune complex mediated vasculitis and specific antibody directed organ damage account for many of the clinical manifestations. Our team has identified abnormalities in various peripheral immune cell compartments, including dendritic cells and their interaction with other immune cells such as Th17 cells, regulatory T and B cells in lupus disease development. However, the aetiology of SLE remains unclear.

One of the main challenges in studying the pathogenesis of lupus is related to the heterogeneity in its clinical manifestations. Our cluster analyses have revealed several prognostically distinct clinical patterns in SLE patients. Lupus nephritis (LN) has been shown to be the most prominent feature of a unique patient cluster. Intriguingly, while some SLE patients experience recurrent nephritic flares, a substantial proportion of patients do not develop nephritis during the entire disease course. Genome wide association studies by us and others have revealed genetic variants that predispose some SLE patients to develop nephritis. We hypothesise that LN patients may represent a distinct sub-group of SLE patients with unique pathogenic attributes, including the dysregulation in various leukocyte responses. We study changes in the function and behaviour of autoreactive T and B lymphocytes, and interplay between adaptive and innate immune cellular responses in SLE using different platforms, including stem cell technology. In addition, we employ the single cell profiling to study peripheral leukocyte transcriptional signature and to use scRNA-sequencing to track leukocyte subset changes longitudinally during different phases of disease in selected SLE and LN patients, aiming to identify the key subsets that contribute to the development of LN. Findings from this study could reveal novel cellular or molecular targets for further investigation as therapeutic or biomarker candidates.

Our Division has an international reputation of excellence in clinical studies and trials in major rheumatic diseases, particularly lupus, rheumatoid arthritis and spondyloarthritis. This is based on a systemic and meticulous recording of disease manifestations, course of illness and response to treatment. Notably in 2012, our Division co-founded a multi-national, multi-centre SLE study group, the Asia Pacific Lupus Collaboration (APLC). The APLC has determined to pool resources to create the largest cohort of lupus patients ever studied and has since facilitated multiple epidemiological studies that produce robust evidence based recommendations for the ongoing management of SLE. For example, the APLC has successfully developed a clinical tool, the Lupus Low Disease Activity State (LLDAS), as an endpoint for clinical trials, treat-to-target studies and clinical practice.

SLE research

Histo-pathological features of lupus nephritis in NZBW F1 mice


Selected Publications

 

Journal impact factor

(2022)

 


CS Lau, C Gallacher, P Ross, JJF Belch.

Rheumatoid arthritis snake oil or fish oil?

Rheumatology (Oxford) 1991; 30: 72-73.

 

7.580

CS Lau, M McLaren, JJF Belch.

Factor VIII von Willebrand Factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon. Rheumatology (Oxford) 1991; 30(6): 433-436.

 

7.580

 

JJF Belch, CS Lau, CD Forbes.

Iloprost and risk of thrombo-embolism.

American Journal of Medicine 1991; 91(6): 666-667.

 

4.965

CS Lau, A O'Dowd, JJF Belch.

White blood cell activation in the Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome.

Annals of the Rheumatic Diseases 1992; 51: 249-252.

 

19.103

CS Lau, AB Bridges, A Muir, N Scott, A Bancroft, JJF Belch.

Further evidence of white cell activation in patients with Raynaud's phenomenon.

Rheumatology (Oxford) 1992; 31: 375-380.

PMID: 1312815. DOI: 10.1136/ard.51.2.249

 

7.580

J Keys, P Beardon, CS Lau, CC Lang, DG McDevitt.

General practitioner use of non‑steroidal anti‑inflammatory drugs in Tayside and Fife regions.

Journal of the Royal Society of Medicine 1992; 85: 442-445.

 

5.344

CS Lau, JJF Belch.

The in vitro free radical scavenging effects of tenidap, a dual cyclo‑oxygenase and 5‑lipoxygenase inhibitor a preliminary study.

Mediators of Inflammation 1993, 1(2): 141-143.

 

4.711

CS Lau, M McLaren, M Walker, JJF Belch.

Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon.

Annals of the Rheumatic Diseases 1993; 52: 443-448.

 

19.103

CS Lau, KD Morley, JJF Belch.

Effects of Maxepa fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis a double blind placebo controlled study.

Rheumatology (Oxford) 1993; 32: 982-989.

 

7.580

CS Lau, M McLaren, J Hanslip, M Kerr, JJF Belch.

Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis.

Annals of the Rheumatic Diseases 1993; 52: 643-649.

 

19.103

CC Mok, CS Lau, SP Poon.

Primary nocardial meningitis in systemic lupus erythematosus.

Rheumatology (Oxford) 1995; 34(2): 178-181.

 

7.580

CC Mok, YL Kwong, CS Lau.

Secondary acute myeloid leukaemia with 7q-complicating azathioprine treatment for rheumatoid arthritis.

Annals of the Rheumatic Diseases 1995; 54(2): 155-156.

 

19.103

CS Lau, AR Saniabadi, JJF Belch.

Reduced red blood cell deformability in patients with rheumatoid vasculitis: Improvement after in vitro treatment with dipyridamole.

Arthritis and Rheumatology 1995; 38(2): 248-253.

 

9.002

JJF Belch, HA Capell, ED Cook, JDT Kirby, CS Lau, R Madhok, E Murphy, M Steinberg.

Oral iloprost as a treatment for Raynaud's syndrome. A double-blind multi-centre placebo controlled study.

Annals of the Rheumatic Diseases 1995; 54: 197-200.

 

19.103

CS Lau, CC Mok and YET Chan

Assessing systemic lupus erythematosus activity using plasma factor VIII von Willebrand factor antigen

Rheumatology (Oxford) 1995, 34(1):8.

 

7.580

YL Lau, CS Lau, SY Chan, J Karlberg, MW Turner.

Mannose-binding protein in Chinese with systemic lupus erythematosus.

Arthritis and Rheumatology 1996; 39 (4): 706-708.

 

9.002

CC Mok, CS Lau.

Dapsone syndrome in cutaneous lupus erythematosus.

Journal of Rheumatology 1996; 23(4): 766-768.

 

4.666

CC Mok, CS Lau, CR Kumana.

Polymyalgia rheumatica as the rheumatological manifestation of myelodysplastic syndrome in a Chinese patient.

Rheumatology (Oxford) 1996; 35(5): 496-497.

 

7.580

CC Mok, CS Lau.

Lack of association between prolactin levels and clinical activity in patients with systemic lupus erythematosus.

Journal of Rheumatology 1996; 23(12): 2185-2186.

 

4.666

CC Mok, KY Yuen, CS Lau.

Nocardiosis in systemic lupus erythematosus.

Seminars in Arthritis and Rheumatism 1997; 26 (4): 675-683.

 

4.7

EYT Chan, JWM Lawton, AKW Lie, CS Lau.

Autoantibody formation after allogeneic bone marrow transplantation: correlation with the reconstitution of CD5+ B cells and occurrence of graft-versus-host disease.

Pathology 1997; 29: 184-188.

 

5.306

CC Mok, CS Lau, CF Tam.

Prolactin profile in a cohort of Chinese systemic lupus erythematosus patients.

Rheumatology (Oxford) 1997; (36)9: 986-989.

 

7.580

WL Lim, KF Wong, CS Lau.

Parvovirus b19 infection in Hong Kong.

Journal of Infection, 1997, v. 35 n. 3, p. 247-249.

http://dx.doi.org/10.1016/S0163-4453(97)92928-5

 

6.072

CS Lau, MY Mok.

Lupus in Asia. Editorial.

JAMA 1998 14 (2): 5-7.

 

56.272

KH Wong, JWM Lawton, SKL Cheng, SS Lee, CS Lau.

Measurement of anti-dsDNA a comparative study of two ELISA and the Crithidia assay.

Pathology 1998 30: 57-61.

 

5.306

CC Mok, CS Lau, EYT Chan, RWS Wong.

Acute transverse myelopathy in systemic lupus erythematosus clinical presentation, treatment and outcome.

Journal of Rheumatology 1998; 25(3): 467-473.

 

4.666

CC Mok, CS Lau, RWS Wong.

Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.

Arthritis and Rheumatology 1998; 41 (5): 831-837.

 

9.002

CC Mok, CS Lau, RW Wong.

Toxicities of dapsone in the treatment of cutaneous manifestations of rheumatic diseases.

Journal of Rheumatology 1998; 25(6): 1246-1247.

 

4.666

CC Mok, JS Lanchbury, DW Chan, CS Lau.

Interleukin-10 promoter polymorphisms in southern Chinese patients with systemic lupus erythematosus.

Arthritis and Rheumatology 1998; 41(6): 1090-1095.

 

9.002

CTK Ho, CC Mok, CS Lau, RWS Wong.

Late-onset systemic lupus erythematosus in southern Chinese.

Annals of the Rheumatic Diseases 1998; 57(7): 437-440.

 

19.103

CC Mok, CS Lau, RWS Wong.

Risk factors for avascular bone necrosis in systemic lupus erythematosus. Rheumatology (Oxford) 1998; 37 (8): 895-900.

 

7.580

WK Ip, SY Chan, CS Lau, YL Lau.

Association of systemic lupus erythematosus with promoter polymorphisms of mannose binding lectin gene.

Arthritis and Rheumatology 1998; 41 (9): 1663-1668.

 

9.002

CC Mok, CS Lau, RWS Wong.

Clinical characteristics, treatment, and outcome of adult onset Still's disease in southern Chinese.

Journal of Rheumatology 1998; 25 (12): 2345-2351.

 

4.666

CC Mok, CS Lau, KW Lee, RWS Wong.

Hyperprolactinaemia in males with systemic lupus erythematosus.

Journal of Rheumatology 1998; 25(12): 2357-2363.

 

4.666

CC Mok, RWS Wong and CS Lau.

Kienbock’s disease in rheumatoid arthritis.

Rheumatology (Oxford) 1998; 37(7): 796-797.

 

7.580

CC Mok, CS Lau, RWS Wong.

Still’s disease in an 80-year-old woman.

Age and Ageing 1998; 27: 407-409.

 

10.668

CC Mok, CS Lau, JS Lanchbury.

Interleukin-10 promoter polymorphism and lupus nephritis: Reply.

Arthritis and Rheumatism Mar 1999, 42(3) 591-593.

 

9.002

CC Mok, RWS Wong, CS Lau.

Ovarian failure and flares of systemic lupus erythematosus.

Arthritis and Rheumatology 1999 Jun;42(6):1274-80

DOI: 10.1002/1529-0131(199906)42:6<1274:AID-ANR26>3.0.CO;2-B

 

9.002

MF Yuen, CS Lau, YL Lau, W Wong, C Cheng, CL Lai.

Mannose binding lectin gene mutations are associated with progression of liver disease in chronic hepatitis B infection.

Hepatology 1999;29(4):1248-1251.

 

17.425

CC Mok, RWS Wong, CS Lau.

Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long term outcome.

American Journal of Kidney Diseases 1999; 34(2): 315-323.

 

8.860

AWC Kung, TM Chan, CS Lau, RWS Wong, SSC Yeung.

Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: A randomised controlled trial comparing calcitriol and hormonal replacement therapy.

Rheumatology (Oxford) 1999; 38(12): 1239-1244.

 

7.580

GC Fong, RT Cheung, SL Ho, CS Lau.

Brainstem tuberculoma mimicking glaucoma.

Neurology 1999; 53 (8): 1894-1895.

 

9.91

CC Mok, KW Lee, CTK Ho, CS Lau, RWS Wong.

A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population.

Rheumatology (Oxford) 2000; 39(4): 399-406.

 

7.580

BMY Cheung, CS Lau, RYH Leung, KK Tong, CR Kumana.

Plasma adrenomedullin level in systemic lupus erythematosus.

Rheumatology (Oxford) 2000;39(7):804-805.

 

7.580

CC Mok, WM Wong, TWH Shek, CTK Ho, CS Lau, CL Lai.

Cumulative hepatotoxicity induced by continuous low-dose cyclophosphamide therapy.

The American Journal of Gastroenterology 2000; 95(3): 845-846.

 

10.864

WK Ip, YL Lau, SY Chan, CC Mok, D Chan, KK Tong, CS Lau.

Mannose-binding lectin and rheumatoid arthritis in southern Chinese.

Arthritis and Rheumatology 2000; 43 (8): 1679-1687.

 

9.002

I Lambrinoudaki, DTM Chan, CS Lau, RWS Wong, SSC Yeung, AWC Kung.

Effect of calcitriol on bone mineral density in premenopausal Chinese women taking chronic steroid therapy. A randomized, double-blind, placebo-controlled study.

Journal of Rheumatology 2000; 27(7): 1759-1765.

 

4.666

TM Chan, FK Li, CSO Tang, RWS Wong, GX Fang, YL Ji, CS Lau, AKM Wong, MKL Tong, KW Chan, and KN Lai, for the Hong Kong – Guangzhou Nephrology Study Group.

Efficacy of Mycophenolate Mofetil in the treatment of patients with diffuse proliferative lupus nephritis.

New England Journal of Medicine 2000; 343(16): 1156-1162.

 

91.245

WK Ip, YL Lau, SY Chan, CC Mok, D Chan, CS Lau.

Mannose-binding lectin and rheumatoid arthritis in southern Chinese.

Arthritis and Rheumatology 2000; 43(8): 1679-1687.

 

9.002

CC Mok, CS Lau, RWS Wong.

Use of exogenous estrogens in systemic lupus erythematosus. Seminars in Arthritis and Rheumatism 2001; 30(6): 426-435.

 

4.7

TG Woodworth, DE Furst, V Strand, J Kempeni, H Fenner, CS Lau, F Miller, R Day, J Lipani, P Brooks.

Standardizing assessment of adverse effects in rheumatology clinical trials. Status of OMERACT Toxicity Working Group March 2000; towards a common understanding of comparative toxicity/safety profiles for antirheumatic therapies.

Journal of Rheumatology 2001; 28(5): 1163-1169.

 

4.666

CC Mok, CT Ho, YP Siu, KW Chan, TH Kwan, CS Lau, RW Wong, TC Au.

Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens.

American Journal of Kidney Diseases 2001; 38(2): 256-264.

 

8.860

CC Mok, CS Lau, RWS Wong.

Neuropsychiatric manifestations and their clinical associations in southern Chinese patients with systemic lupus erythematosus.

Journal of Rheumatology 2001; 28(4): 766-771.

 

4.666

CC Mok, CTK Ho, YP Siu, KW Chan, TH Kwan, CS Lau, RWS Wong, TC Au.

Daily and nocturnal haemodialysis: How do they stack up?

American Journal of Kidney Diseases, 2001;38(2) 225-239.

http://dx.doi.org/10.1053/ajkd.2001.26079

 

8.86

CC Mok, CTK Ho, KW Chan, CS Lau, RWS Wong.

Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine.

Arthritis and Rheumatology 2002; 46(4): 1003-1013.

 

9.002

BP Tsao, RM Cantor, JM Grossman, SK Kim, N Strong, CS Lau, CJ Chen, N Shen, EM Ginzler, R Goldstein,

KC Kalunian, FC Arnett, DJ Wallace, BH Hahn.

Linkage and interaction of loci on 1q23 and 16q12 may contribute to susceptibility to systemic lupus erythematosus.

Arthritis and Rheumatology 2002; 46(11): 2928-2936.

 

9.002

CC Mok, TC Cheung, CT Ho, KW Lee, CS Lau, RW Wong. Behcet’s disease in southern Chinese patients.

Journal of Rheumatology 2002; 29(8): 1689-1693.

 

4.666

BP Tsao, JM Grossman, G Riemekasten, N Strong, J Kalsi, DJ Wallace, CJ Chen, CS Lau, EM Ginzler, R Goldstein,

KC Kalunian, JB Harley, FC Arnett, BH Hahn, RM Cantor.

Familiality and co-occurrence of clinical features of systemic lupus erythematosus.

Arthritis and Rheumatology 2002; 46(10): 2678-2685.

 

9.002

MY Mok, Y Lo, DTM Chan, RWS Wong and CS Lau

Efficacy of Isoniazid Chemoprophylaxis for Tuberculous Infection in Patients with systemic Lupus Erythematosus in an endemic area.

Arthritis and Rheumatology 2002; 46 (9): pp.S60-60.

 

9.002

KC Lai, CS Lau, WY Ip, BC Wong, WM Hui, WH Hu, RW Hong, SK Lam.

Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long term NSAIDs: a double-blind , placebo-controlled trial.

Alimentary Pharmacology and Therapeutics 2003; 17(6): 799-805.

 

8.171

Y Ren, J Tang, MY Mok, AWK Chan, A Wu, CS Lau.

Increased apoptotic neutrophils and macrophages and impaired macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus.

Arthritis and Rheumatology 2003; 48(10): 2888-2897.

 

9.002

CC Mok, CTK Ho, RWS Wong, CS Lau.

Damage accrual in southern Chinese patients with systemic lupus erythematosus.

Journal of Rheumatology 2003; 30(7): 1513-1519.

 

4.666

CC Mok, CS Lau, RWS Wong.

Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open-label study.

American Journal of Medicine 2003; 115(1): 59-62.

 

4.965

J Woo, E Lau, CS Lau, P Lee, J Zhang, T Kwok, C Chan, P Chiu, KM Chan, A Chan, D Lam.

Socioeconomic impact of osteoarthritis in Hong Kong: Utilization of health and social services, and direct and indirect costs.

Arthritis and Rheumatology 2003; 49(4): 526-534.

 

9.002

DSS Kumar, CS Lau, WK Chan, D Yang, HY Cheung, F Chen, KD Hyde.

Immunomodulatory compounds from Pestalotiopsis leucothes,an endophytic fungus from Tripterygium wilfordii.

Life Sciences Nov 2005; 78(2) 147-156.

 

5.037

CC Mok, KY Ying, CS Lau, CW Yim, WL Ng, RWS Wong, TC Au.

Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: An open-label trial.

American Journal of Kidney Diseases 2004; 43(2): 269-276.

 

8.860

WP Chong, WK Ip, CS Lau, TM Chan, L Padyukov, YL Lau.

Common NOD2 polymorphisms in Hong Kong Chinese patients with systemic lupus erythematosus.

Rheumatology (Oxford) 2004; 43(1): 104-105.

 

7.580

EMY Chu, KY Chiu, RWS Wong, WM Tang, CS Lau.

Translation and validation of arthritis impact measurement scales 2 into Chinese: CAIMS2.

Arthritis and Rheumatology 2004; 51(1): 20-27.

 

9.002

CC Mok, KY Ying, S Tang, CY Leung, KW Lee, WL Ng, RWS Wong, CS Lau.

Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis.

Arthritis and Rheumatology 2004; 50(8): 2559-2568.

 

9.002

J Woo, E Lau, P Lee, T Kwok, CS Lau, C Chan, P Chiu, E Li, A Sham, D Lam.

Impact of osteoarthritis on quality of life in a Hong Kong Chinese population.

Journal of Rheumatology 2004; 31(12): 2433-2438.

 

4.666

CR Kumana, GTY Cheung, CS Lau.

Severe digital ischaemia treated with phosphodiesterase inhibitors.

Annals of the Rheumatic Diseases 2004;63(11):1522-1524.

 

19.103

MY Mok, PY Leung, TH Lao, Y Lo, TM Chan, WS Wong, CS Lau.

Clinical predictors of fetal and maternal outcome in Chinese patients with systemic lupus erythematosus.

Annals of the Rheumatic Diseases 2004; 63(12): 1705-1706.

 

19.103

MY Mok, Y Lo, PY Leung, CS Lau.

Pregnancy outcome in patients with adult onset Still’s disease.

Journal of Rheumatology 2004; 31(11): 2307-2309.

 

4.666

MY Mok, Y Lo, TM Chan, WS Wong, CS Lau.

Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during corticosteroid therapy.

Journal of Rheumatology 2005; 32: 609-615.

 

4.666

MY Mok, EY Chan, DY Fong, KF Leung, WS Wong, CS Lau.

Antiphospholipid antibody profiles and their clinical associations in Chinese patients with systemic lupus erythematosus.

Journal of Rheumatology 2005; 32: 622-628.

 

4.666

EKP Kong, L Prokunina-Olsson, WHS Wong, CS Lau, TM Chan, M Alarcón-Riquelme, YL Lau.

A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese.

Arthritis and Rheumatology 2005; 52(4): 1058-1062.

 

9.002

MW Ng, CS Lau, TM Chan, WHS Wong, YL Lau.

Polymorphisms of the toll-like receptor 9 (TLR9) gene with systemic lupus erythematosus in Chinese.

Rheumatology (Oxford) 2005;44(11);1456-1457.

 

7.580

SSD Kumar, CS Lau, JMF Wan, D Yang, KD Hyde.

Immunomodulatory compounds from pestalotiopsis leucothës, an endophytic fungus from Tripterygium wilfordii.

Life Sciences 2005; 78(2): 147-156.

 

5.037

AN Malaviya, CS Lau, RR Singh.

The Lancet’s chronic disease series.

Lancet 2006; Feb 18;367 (9510): 563.

https://doi.org/10.1016/S0140-6736(06)68212-3

 

79.321

CS Lau.

Collateral benefits of fish oil therapy for rheumatoid arthritis.

Journal of Rheumatology. 2006 Oct;33(10):1931-1933.

PMID: 17014011

 

4.666

A Mak, BMY Cheung, CC Mok, R Leung, CS Lau.

Adrenomedullin: A potential disease activity marker and suppressor of nephritis activity in systemic lupus erythematosus.

Rheumatology (Oxford) 2006; 45(10): 1266-1272.

 

7.580

CC Mok, KY Ying, WL Ng, KW Lee, CH To, CS Lau, WS Wong, TC Au.

Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide.

American Journal of Medicine 2006;119(4):335-e25.

 

4.965

S Kavikondala, Y Nie and CS Lau

Report on the Second Asia Autoimmunity Forum 3-5 March 2006, Hong Kong.

Autoimmunity Reviews. Amsterdam, New York: Elsevier, 2006, 6(2), 115-118.

 

9.754

J X Zhang, J Woo, CS Lau, P Lee, P Chiu, D Lam.

Effects of use of alternative therapies on quality of life and healthcare spending.

The American Journal of Chinese Medicine. 2007; 35 (2): 183-193.

 

4.667

MY Mok, S Wong, TM Chan, DYT Gong, WS Wong, CS Lau.

Non-tuberculous mycobacterial infection in patients with systemic lupus erythematosus.

Rheumatology (Oxford) 2007; 46(2): 280-284.

 

7.580

MY Mok, EY Chan, WS Wong, CS Lau.

Intrathecal immunoglobulin production in patients with systemic lupus erythematosus with neuropsychiatric manifestations.

Annals of the rheumatic diseases, 2007; 66(6), 846-847.

http://dx.doi.org/10.1136/ard.2006.061069

 

19.103

EK Kong, WP Chong, WH Wong, CS Lau, TM Chan, PK Ng, YQ Song, W Mak, YL Lau.

p21 gene polymorphisms in systemic lupus erythematosus.

Rheumatology (Oxford) 2007; 46(2): 220-226.

 

7.580

MY Mok, BMY Cheung, Y Lo, RYH Leung, WS Wong, CS Lau.

Elevated plasma adrenomedullin and vascular manifestations in patients with systemic sclerosis.

Journal of Rheumatology 2007; 34(11): 2224-2249.

PMID: 17937467

 

4.666

MY Mok, WK Ip, CS Lau, Y Lo, WHS Wong, YL Lau.

Mannose-binding lectin and susceptibility to infection in Chinese patients with systemic lupus erythematosus.

Journal of Rheumatology 2007; 34: 1270-1276.

 

4.666

CS Lau, PH Feng.

Rheumatology without borders.

Nature Reviews Rheumatology 2007; 3(6): 305.

http://dx.doi.org/10.1038/ncprheum0509

 

20.543

CS Lau, HY Kim and K Nishioka

Rheumatology in the Asia Pacific Region - Opportunities and Challenges.

Nature Reviews Rheumatology 2007; 3(3): 119.

 

20.543

HO Siu, W Yang, CS Lau, TM Chan, RW Wong, WH Wong, YL Lau, ME Alarcon-Riquelme.

Association of a haplotype of IRF5 gene with systemic lupus erythematosus in Chinese.

Journal of Rheumatology 2008; 35(2): 360 – 362.

 

4.666

JJF Belch, S McSwiggan, CS Lau.

Macrovascular disease in systemic sclerosis: The tip of an iceberg?

Rheumatology (Oxford) 2008; 47 (Suppl 5): 16-17.

 

7.580

CS Lau and PH Feng

An international journal from the Asia-Pacific: an evolution.

International Journal of Rheumatic Disease. 2008, 11(1):1-3.

http://dx.doi.org/10.1111/j.1756-185X.2008.00341.x

 

2.454

CS Lau, A Mak.

The socioeconomic burden of SLE.

Nature Reviews Rheumatology 2009; 5(7): 400-404.

 

20.543

WL Yang, MH Zhao, N Hirankarn, CS Lau, CC Mok, TM Chan, RWS Wong, KW Lee, MY Mok, SN Wong, Y Avihingsanon, IONG Ng, TL Lee, MHK Ho, PPW Lee, WHS Wong, PC Sham, YL Lau.

ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai.

Human Molecular Genetics 2009; 18 (11): 2063-2070.

 

6.15

A Mak, AAC Cheak, JYS Tan, HC Su, RCM Ho, CS Lau.

Mycophenolate mofetil is as efficacious as, but safer than cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression.

Rheumatology (Oxford) 2009; 48(8): 944-952.

 

7.580

DM Reid, JP Devogelaer, K Saag, C Roux, CS Lau, JY Reginster, P Papanstasiou, A Ferreira, F Hartl, T Fashola, P Mesenbrink, PN Sambrook.

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomized controlled trial.

Lancet 2009; 373(9671): 1253-1263.

 

79.321

KH Yiu, S Wang, MY Mok, GC Ooi, PL Khong, KFH Mak, KF Lam, CS Lau, HF Tse.

Pattern of arterial calcification in patients with systemic lupus erythematosus.

Journal of Rheumatology 2009; 36(10): 2212-2217.

 

4.666

S Wang, KH Yiu, MY Mok, GC Ooi, PL Khong, KF Mak, CP Lau, CS Lau, HF Tse.

Prevalence and extent of calcification over aorta, coronary and carotid arteries in patients with rheumatoid arthritis.

Journal of Internal Medicine 2009; 266(5): 445-452.

 

8.986

W Yang, N Shen, DQ Ye, Q Liu, Y Zhang, XX Qian, N Hirankarn, D Ying, HF Pan, CC Mok, TM Chan, RW Wong, KW Lee, MY Mok, SN Wong, AM Leung, XP Li, Y Avihingsanon, CM Wong, TL Lee, MH Ho, PP Lee, YK Chang, PH Li, RJ Li, L Zhang, WH Wong, IO Ng, CS Lau, PC Sham, YL Yan, Asian Lupus Genetics Consortium.

Genome-Wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus.

PLoS Genetics 2010; 6(2): e1000841.

 

5.917

YJ Nie, MY Mok, GCF Chan, A Chan, O Jin, S Kavikondala, AKW Lie, CS Lau.

Phenotypic and functional abnormalities of bone marrow-derived dendritic cells in systemic lupus erythematosus.

Arthritis Research and Therapy 2010;12(3):1-12.

 

5.156

O Jin, S Kavikondala, LY Sun, JR Gu, R Fu, MY Mok, A Chan, J Yeung, YJ Nie, CS Lau.

Abnormalities in circulating plasmacytoid dendritic cells in patients with systemic lupus erythematosus.

Arthritis Research and Therapy 2010; 12(4):1-11.

 

5.156

KH Yiu, S Wan, MY Mok, GC Ooi, PL Khong, CP Lau, WH Lai, LY Wong, KF Lam, CS Lau, HF Tse.

Role of circulating endothelial progenitor cells in patients with rheumatoid arthritis with coronary calcification.

Journal of Rheumatology 2010; 37(3): 529 – 535.

 

4.666

MY Mok, HJ Wu, Y Lo, CS Lau.

The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus.

Journal of Rheumatology 2010; 37(10): 2046-2052.

 

4.666

MY Mok, CS Lau.

The burden and measurement of cardiovascular disease in SSc.

Nature Reviews Rheumatology 2010; 6(7): 430-434.

http://dx.doi.org/10.1038/nrrheum.2010.65

 

20.543

CS Lau, T Cheung.

Should clinicians start measuring flow mediated dilation response in patients with systemic lupus erythematosus?

Journal of Rheumatology 2011: 38(7): 1231-1233.

 

4.666

MY Mok, CS Lau, S Chiu, A Tso, Y Lo, LSC Law, KF Mak, WS Wong, PL Khong, KSL Lam.

Systemic Sclerosis is an independent risk factor for increased coronary artery calcium deposition.

Arthritis and Rheumatology 2011; 63(5): 1387-1395.

 

9.002

J Yang, W Yang, N Hirankarn, DQ Ye, Y Zhang, HF Pan, CC Mok, TM Chan, RW Wong, MY Mok, KW Lee, SN Wong, AM Leung, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeeiporn, V Shotelersuk, L Baum, P Kwan, TL Lee, MH Ho, PP Lee, WH Wong, S Zeng, J Zhang, CM Wong, IO Ng, MM Garcia-Barceló, SS Cherny, PK Tam, PC Sham, CS Lau, YL Lau.

ELF1 is associated with systemic lupus erythematosus in Asian populations.

Human Molecular Genetics 2011; 20(3): 601-607.

 

6.15

KH Yiu, HF Tse, MY Mok, CS Lau.

Ethnic differences in cardiovascular risk in rheumatic disease: Focus on Asians.

Nature Reviews Rheumatology 2011 Sep 13(7(10):609-618. PMID:21912432. DOI:10.1038/nrrheum.2011.126

 

20.543

KH Yiu, S Wang, MY Mok, GC Ooi, PL Khong, CS Lau,

HF Tse.

Relationship between cardiac valvular and arterial calcification in patients with rheumatoid arthritis and systemic lupus erythematosus.

Journal of Rheumatology 2011; 38(4): 621-627.

 

4.666

C Roux, DM Reid, JP Devogelaer, K Saag, CS Lau, JY Reginster, P. Papanastasiou, C BucciRechtweg, G Su, PN Sambrook.

Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.

Osteoporosis International 2012 Mar;23(3):1083-90.

PMID 21975559. DOI: 10.1007/s00198-011-1800-1

 

4.507

VS Chan, YJ Nie, N Shen, S Yan, MY Mok, CS Lau.

Distinct roles of myeloid and plasmacytoid dendritic cells in systemic lupus erythematosus.

Autoimmunity Reviews 2012; 11(12): 890-897.

https://doi.org/10.1016/j.autrev.2012.03.004

 

9.754

VS Chan, HL Tsang, R Tam,L Lu, CS Lau.

B-cell Targeted Therapies in Systemic Lupus Erythematosus.

Cellular and Molecular Immunology 2013;10(2):133-142.

https://doi.org/10.1038/cmi.2012.64

 

11.53

W Yang, H Tang, Y Zhang, X Tang, J Zhang, L Sun, J Yang, Y Cui, L Zhang, N Hirankarn, H Cheng, HF Pan, J Gao, TL Lee, Y Sheng, CS Lau, Y Li, TM Chan, X Yin, D Ying, Q Lu, AM Leung, X Zuo, X Chen, KL Tong, F Zhou, Q Diao, NK Tse, H Xie, CC Mok, F Hao, SN Wong, B Shi, KW Lee, Y Hui, MH Ho, B Liang, PP Lee, H Cui, Q Guo, BH Chung, X Pu, Q Liu, X Zhang, C Zhang, CY Chong, F Fang, RW Wong, Y Sun, MY Mok, XP Li, Y Avihingsanon, Z Zhai, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, F Gao, V Shotelersuk, X Kang, SK Ying, L Zhang, WH Wong, D Zhu, SK Fung, F Zeng, WM Lai, CM Wong, IO Ng, MM Garcia-Barceló, SS Cherny, N Shen, PK Tam, PC Sham, DQ Ye, S Yang, X Zhang, YL Lau.

Meta-analysis followed by replication identifies loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as associated with systemic lupus erythematosus in Asians.

The American Journal of Human Genetics – Cell 2013; 92(1): 41-51.

 

9

PH Li, WH Wong, TL Lee, CS Lau, TM Chan, AM Leung, KL Tong, NK Tse, CC Mok, SN Wong, KW Lee, MH Ho, PP Lee, CY Chong, RW Wong, MY Mok, SK Ying, SK Fung, WM Lai, W Yang, YL Lau.

Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese.

Rheumatology (Oxford) 2013; 52(2): 337-345.

 

7.580

H Gill, S Liu, A Ip, F Loong, EY Lee, RY Leung, CS Lau, WK Ip, S Tam, YL Kwong.

Unremitting pyrexia, pancytopenia, hepatosplenomegaly and extreme hyperferritinemia.

American Journal of Hematology 2013; 88(7): 626-629.

 

10.047

A Mak, DA Isenberg, CS Lau.

Global trends, potential mechanisms and early detection of organ damage in SLE.

Nature Reviews Rheumatology. 2013, 9(5), 301-10.

http://dx.doi.org/10.1038/nrrheum.2012.208

 

20.543

G Kwok, A Kan, RY Leung, S Tam, CS Lau and YL Kwong.

Pyrexia, massive hepatomegaly, and extreme hyperferritinemia.

American Journal of Medicine. 2014, 127(6): e13-e14.

http://dx.DOI.org/10.1016/j.amjmed.2014.01.015

 

4.965

J Zhang, Y Zhang, J Yang, L Zhang, L Sun, HF Pan, N Hirankarn, D Ying, S Zeng, TL Lee, CS Lau, TM Chan, AM Leung, CC Mok, SN Wong, KW Lee, MH Ho, PP Le, BH Chung, CY Chong, RW Wong, MY Mok, WH Wong, KL Tong, NK Tse, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, V Shotelersuk, SK Ying, SK Fung, WM Lai, MM Garcia-Barcelo, SS Cherny, PK Tam, Y Cui, PC Sham, S Tang, DQ Ye, XJ Zhang, YL Lau, W Yang.

Three SNPs in chromosome 11q23.3 are independently associated with systemic lupus erythematosus in Asians.

Human Molecular Genetics 2014; 23 (2): 524-533.

10.1093/hmg/ddt424

 

6.15

N Sharma, CS Lau, I Dpherty, D Harbutt.

Medical school pedagogy should be culture-dependent.

Academic Medicine 2014 Feb;89(1):194. PMID: 24473566.

 

6.893

S Yan, YY Lok, LW Lu, CS Lau, VSF Chan.

MicroRNA regulation in systemic lupus erythematosus pathogenesis.

Immune Network 2014; 14(3):138-148.

https://doi.org/10.4110/in.2014.14.3.138

 

6.303

X Lin, K Rui, J Deng, J Tian, X Wang, S Wang, KH Ko, Z Jiao, VSF Chan, CS Lau, X Cao, L Lu.

Th17 cells play a critical role in the development of experimental Sjögren’s syndrome.

Annals of the Rheumatic Diseases 2015;74: 1302–1310.

DOI:10.1136/annrheumdis-2013-204584

 

19.103

Y Zhang, YF Wang, J Yang, J Zhang, L Sun, N Hirankarn, HF Pan, CS Lau, TM Chan, TL Lee, A Leung, CC Mok, L Zhang, JJ Shen, SN Wong, K Lee, MH Ho, PP Lee, BH Chung, CY Chong, RW Wong, MY Mok, WH Wong, KL Tong, NK Tse, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, V Shotelersuk, SK Ying, SK Fung, WM Lai, CM Wong, IO Ng, MM Garcia-Barcelo,

SS Cherny, PK Tam, PC Sham, S Yang, DQ Ye, Y Cui, XJ Zhang, W Yang, YL Lau.

Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus.

Arthritis Research and Therapy 2015;17(1):1-9.

DOI:10.1186/s13075-015-0577-6

 

5.156

CS Lau, F Chia, A Harrison, TW Hsieh, R Jain, SM Jung, M Kishimoto, A Kumar, KP Leong, ZQ Li, JJ Lichauco, W Louthrenoo, SF Luo, P Nash, CT Ng, SH Park, BPP Suryana, P Suwannalal, LK Wijaya, K Yamamoto, Y Yang, SS Yeap.

APLAR rheumatoid arthritis treatment recommendations.

International Journal of Rheumatic Diseases 2015 ;18(7): 685-713.

https://doi.org/10.1111/1756-185X.12754

 

2.454

Y Zhang, J Zhang, J Yang, Y Wang, L Zhang, X Zuo, L Sun, HF Pan, N Hirankarn, T Wang, R Chen, D Ying, S Zeng, JJ Shen, TL Lee, CS Lau, TM Chan, AM Leung, CC Mok, SN Wong, KW Lee, MH Ho, PP Lee, BH Chung, CY Chong, RW Wong, MY Mok, WH Wong, KL Tong, NK Tse, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, V Shotelersuk, SK Ying, SK Fung,

WM Lai, CM Wong, IO Ng, MM Garcia-Barcelo, SS Cherny, PK Tam, PC Sham, S Yang, DQ Ye,Y Cui, XJ Zhang, YL Lau, W Yang.

Meta-analysis of GWAS on two Chinese populations followed by replication identifies novel genetic variants on the X chromosome associated with systemic lupus erythematosus.

Human Molecular Genetics 2015; 24(1): 274-284.

DOI:10.1093/hmg/ddu429

 

6.15

RCY Tam, ALH Lee, WL Yang, CS Lau, VSF Chan.

Systemic lupus erythematosus patients exhibit reduced expression of CLEC16A isoforms in peripheral leukocytes.

International Journal of Molecular Sciences 2015; 16(7): 14428-14440.

https://doi.org/10.3390/ijms160714428

 

5.542

Y Chen, HY Chung, CT Zhao, A Wong, Z Zhen, HHL Tsang, CS Lau, HF Tse, KH Yiu.

Left ventricular myocardial dysfunction and premature atherosclerosis in patients with axial Spondyloarthritis. Rheumatology (Oxford). 2015 Feb;54(2): 292-301.

PMID: 25173350 DOI:10.1093/rheumatology/keu337.

 

7.580

J Zhang, L Zhang, Y Zhang, J Yang, M Guo, L Sun, HF Pan, N Hirankarn, D Ying, S Zeng, TL Lee, CS Lau, TM Chan, AM Leung, CC Mok, SN Wong, KW Lee,MH Ho, PP Lee, BH Chung, CY Chong, RW Wong, MY Mok, WH Wong, KL Tong, NK Tse, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, V Shotelersuk, SK Ying, SK Fung, WM Lai, MM Garcia-Barceló, SS Cherny, PC Sham, Y Cui, S Yang, DQ Ye, XJ Zhang,YL Lau, W Yang.

Gene-based meta-analysis of genome-wide association study identifies independent single-nucleotide polymorphisms in ANXA6 as being associated with systemic lupus erythematosus in Asian populations.

Arthritis and Rheumatology 2015; 67(11): 2966-2977.

DOI:10.1002/art.39275

 

9.002

K Franklyn, CS Lau, SV Navarra, W Louthrenoo, A Lateef, L Hamijoyo, CS Wahono, SL Chen, O Jin, S Morton, A Hoi, M Huq, M Nikpour, EF Morand. Asia-Pacific Lupus Collaboration.

Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).

Annals of the Rheumatic Diseases 2016; 75(9): 1615-1621. DOI:10.1136/annrheumdis-2015-207726

 

19.103

AM Leung, D Farewell, CS Lau, EH Choy.

Defining criteria for rheumatoid arthritis patient-derived disease activity score that correspond to Disease Activity Score 28 and Clinical Disease Activity Index based disease states and response criteria.

Rheumatology (Oxford) 2016; 55(11): 1954-1958.

DOI:10.1093/rheumatology/kew279

 

7.580

JY Chen, LY Wu, MYT Mok, JYJ Wu, KE Lintner, CM Wang, EK Chung, Y Yang, B Zhou, H Wang, DJ Yu, A Alhomosh, K Jones, CH Spencer, HN Nagaraja, YL Lau, CS Lau, YC Yu.

Effects of complement C4 gene copy number variations, size dichotomy, and C4A deficiency on genetic risk and clinical presentation of systemic lupus erythematosus in East Asian populations.

Arthritis and Rheumatology 2016, 68: 1442-1453.

DOI:10.1002/art.39589

 

9.002

Y Zhang, J Yang, J Zhang, L Sun, N Hirankarn, HF Pan, CS Lau, TM Chan, TL Lee, AM Leung, CC Mok, L Zhang, Y Wang, JJ Shen, SN Wong, KW Lee, MH Ho, PP Lee, BH Chung, CY Chong, RW Wong, MY Mok, WH Wong, KL Tong, NK Tse, XP Li, Y Avihingsanon, P Rianthavorn, T Deekajorndej, K Suphapeetiporn, V Shotelersuk, SK Ying, SK Fung, Lai WM, CM Wong, IO Ng, MM Garcia-Barcelo, SS Cherny, Y Cui, PC Sham, S Yang, DQ Ye, XJ Zhang, YL Lau, W Yang.

Genome-wide search followed by replication reveals genetic interaction of CD80 and ALOX5AP associated with systemic lupus erythematosus in Asian populations.

Annals of the Rheumatic Diseases 2016; 75(5): 891-898.

DOI:10.1136/annrheumdis-2014-206367

 

19.103

Z Wang, H Yin, CS Lau, Q Lu.

Histone posttranslational modifications of CD4(+) T cell in autoimmune diseases.

International Journal of Molecular Sciences 2016, 17: 1547.

DOI:10.3390/ijms17101547

 

5.542

S Yan, LY Yim, CY Tam, WK Chan, L Lu, CS Lau, VSF Chan.

MicroRNA-155 mediates augmented CD40 expression in bone marrow derived plasmacytoid dendritic cells in symptomatic lupus-prone NZB/W F1 mice.

International Journal of Molecular Sciences. 2016, 17: 1282.

DOI: https://doi.org/10.3390/ijms17081282

 

5.542

V Golder, R Kandane-Rathnayake, AY Hoi, M Huq, W Louthrenoo, Y An, ZG Li, SF Luo, S Sockalingam, CS Lau, MY Mok MY, A Lateef, K Franklyn, S Moron, ST Navarra, L Zamora, YJ Wu, L Hamijoyo, M Chan, S O'Neill, F Goldblatt, E Morand, M Nikpour; Asia-Pacific Lupus Collaboration.

Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort.

Arthritis Research and Therapy 2016; 18 (1): 1-9.

DOI:10.1186/s13075-016-1163-2

 

5.156

Q Zhang, S Ding, H Zhang, H Long, H Wu, M Zhao, V Chan, CS Lau, Q Lu.

Increased Set1 binding at the promoter induces aberrant epigenetic alterations and up-regulates cyclic adenosine 5’-monophosphate response element modulator alpha in systemic lupus erythematosus.

Clinical Epigenetics 2016; 24(8): 126.

DOI:10.1186/s13148-016-0294-2

 

6.551

CS Lau, P Li.

Epidemiology: The effects of AIDS on the prevalence of rheumatic diseases.

Nature Reviews Rheumatology 2017; 13 (1): 8-10.

DOI: 10.1038/nrrheum.2016.196

 

20.543

V Golder, M Huq, K Franklyn, A Calderone, A Lateef, CS Lau, ALH Lee, STV Navarra, T Godfrey, S Oon, AYB Hoi,

EF Morand, M Nikpour.

Does expert opinion match the operational definition of the lupus low disease activity state (LLDAS)? A case-based construct validity study.

Seminars in Arthritis and Rheumatism 2017; 46, 798-803.

DOI: 10.1016/j.semarthrit.2017.01.007

 

4.7

V Golder, R Kandane-Rathnayake, AY Hoi, M Huq, W Louthrenoo, Y An, ZG Li, SF Luo, Z Sockalingam, CS Lau, MYT Mok M, A Lateef, K Franklyn, S Morton, ST Navarra, L Zamora, YJ Wu, L Hamijoyo, M Chan, S O’Neill, F Goldblatt, M Nikpour, EF Morand.

Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study.

Arthritis Research and Therapy 2017; 19 (1): 62.

DOI: 10.1186/s13075-017-1256-6

 

5.156

Q Li, H Wu, W Liao, M Zhao, V Chan, L Li, M Zheng, G Chen, J Zhang, CS Lau, Q Lu.

A comprehensive review of immune-mediated dermatopathology in systemic lupus erythematosus.

Journal of Autoimmunity 2018; 93: 1-15.

https://doi.org/10.1016/j.jaut.2018.07.007

 

7.094

PH Li, TJ Watts, MS Lui, CS Lau, HY Chung.

Recall Urticaria in Adalimumab Hypersensitivity.

Journal of Allergy and Clinical Immunology: In Practice.

May-Jun 2018; 6(3):1032-1033.

DOI: 10.1016/j.jaip.2017.10.031

 

8.861

EYL Au, JS Rosa Duque, CS Lau, E Chan.

A patient with anaphylaxis to diphenhydramine without cross-reactivity to loratidine.

Journal of Allergy and Clinical Immunology: In Practice 2018; 6(3): 1061-1063.

DOI: 10.1016/j.jaip.2017.10.032

 

8.861

IKY Lam, JX Chow, CS Lau, VSF Chan.

MicroRNA-mediated immune regulation in rheumatic diseases.

Cancer Letters 2018 Sept 1, 431:201-212.

DOI: 10.1016/j.canlet.2018.05.044

 

8.679

H Wu, W Liao, Q Li, H Long, H Yin, M Zhao, V Chan, CS Lau, Q Lu

Pathogenic role of tissue-resident memory T cells in autoimmune diseases.

Autoimmunity reviews. 2018 Sep 1;17(9):906-11. https://doi.org/10.1016/j.autrev.2018.03.014

 

9.754

KS Yeung, TL Lee, MY Mok, CCY Mak, W Yang, PCY Chong, PPW Lee, MHK Ho, S Choufani, CS Lau, YL Lau, R Weksberg, BHY Chung.

Cell lineage-specific genome-wide DNA methylation analysis of patients with paediatric-onset systemic lupus erythematosus.

Epigenetics 2019 Feb 26.

https://doi.org/10.1080/15592294.2019.1585176

 

4.528

KH Lee, HY Chung, XP Xu, V Lau, CS Lau.

Apparent diffusion coefficient as an imaging biomarker for spinal disease activity in axial spondyloarthritis.

Radiology 2019 Apr;29(1):121-128.

PMID: 30720403. http://dx.doi.org/10.1148/radiol.2019180960

 

11.105

YH Chan, MC Ngai, Y Chen, MZ Wu, YJ Yu, Z Zhen, K Lai, T Cheung, LM Ho, HY Chung, CS Lau, HF Tse, KH Yiu.

Cumulative rheumatic inflammation modulates the

bone-vascular axis and risk of coronary calcification.

Journal of the American Heart Association 2019 Jun;4;8(11): e011540.

PMID:31130038. DOI: 10.1161/JAHA.118.011540

 

5.501

HHL Tsang, JPY Cheung, CKH Wong, PWH Cheung, CS Lau, HY Chung.

Psychometric validation of the EuroQoL 5-dimension (EQ-5D) questionnaire in patients with spondyloarthritis.

Arthritis Research & Therapy 2019; 21:41.

PMID: 30700326. DOI: 10.1186/s13075-019-1826-x/

 

5.156

HY Chung, ETF Chui, KH Lee, HHLTsang, SCW Chan, CS Lau.

ASDAS is associated with both the extent and intensity of DW-MRI spinal inflammation in active axial spondyloarthritis.

RMD Open. 2019 Aug 6;5(2): e001008.

PMID: 31452930. DOI: 10.1136/rmdopen-2019-001008

 

5.117

LY Yim, CS Lau, VSF Chan

Heightened TLR7/9-induced IL-10 and CXCL13 production with dysregulated NF-ҝB activation in CD11chiCD11b+ dendritic cells in NZB/W F1 mice.

International Journal Molecular Sciences. 2019 Sep 19; 20(18). pii: E4639.

https://www.mdpi.com/1422-0067/20/18/4639

 

5.542

PH Li, TJ Watts, HY Chung, CS Lau.

Fixed drug eruption to biologics and role of lesional patch testing

Journal of Allergy and Clinical Immunology. In Practice 2019 Sep-Oct;7(7):2398-2399.

DOI: 10.1016/j.jaip.2019.06.028

 

8.861

D Li and CS Lau

Combating COVID-19: East meets West

British Journal of General Practice 2020; 70 (696): e442-e443.

DOI: 10.3399/bjgp20X710753. Print 2020 Jul

 

5.386

PH Li, HHF Yeung, CS Lau, EYL Au.

Prevalence, incidence, and sensitization profile of β-lactam antibiotic allergy in Hong Kong.

JAMA Network Open. 2020 May 1;3(5): e204199.

DOI: 10.1001/jamanetworkopen.2020.4199

 

8.48

IF Hung, KC Lung, EY Tso, R Liu, TW Chung, MY Chu, YY Ng, J Lo, J Chan, AR Tam, HP Shum, V Chan, AK Wu, KM Sin, WS Leung, WL Law, DC Lung, S Sin, P Yeung, CC Yip, RR Zhang, AY Fung, EY Yan, KH Leung, JD Ip, AW Chu, WM Chan, AC Ng, R Lee, K Fung, A Yeung, TC Wu, JW Chan, WW Yan, WM Chan, JF Chan, AK Lie, OT Tsang, VC Cheng, TL Que, CS Lau, KH Chan, KK To, KY Yuen.

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.

The Lancet 2020 May 30;395(10238):1695-1704.

DOI: 10.1016/S0140-6736(20)31042-4

 

79.321

PH Li, WWY Wong, ENY Leung, CS Lau, E Au.

Novel pathogenic mutations identified in the first Chinese pedigree of complete C6 deficiency.

Clinical & Translational Immunology 2020; 9: e1148.

DOI: 10.1002/cti2.1148

 

6.161

MH Leung, EHS Choy, CS Lau

Cumulative patient-based disease activity monitoring in rheumatoid arthritis - predicts sustained remission, flare and treatment escalation.

Seminars in Arthritis and Rheumatism. 2020 Aug;50(4):749-758. DOI: 10.1016/j.semarthrit.2020.03.010

 

4.7

PH Li, HH Yeung, CS Lau, EY Au.

Excipient allergy and importance of complete allergy histories.

Journal of Allergy and Clinical Immunology: In Practice 2020; 8: 2122 – 2123.

 

8.861

ETF Chui, HHL Tsang, KH Lee, CS Lau, CH Wong, HY Chung.

MRI inflammation of facet and costovertebral joints is associated with restricted spinal mobility and worsened functional status.

Rheumatology (Oxford). 2020 Sep 1;59(9):2591-2602. PMID:32003811. DOI: 10.1093/rheumatology/kez649

 

7.580

MF Tsoi, MH Chung, MY Cheung, CS Lau, TT Cheung.

Epidemiology of gout in Hong Kong: a population-based study from 2006 to 2016" (ARRT-D-19-00849R2).

Arthritis Research & Therapy 2020 Sep 4:22(1):204.

DOI: 10.1186/s13075-020-02299-5

 

5.156

IF Hung, VC Cheng, X Li, AR Tam, DL Hung, KH Chiu, CC Yip, JP Cai, DT Ho, SC Wong, SS Leung, MY Chu, MO Tang, JH Chen, RW Poon, AY Fung, RR Zhang, EY Yan, LL Chen, CY Choi, KH Leung, TW Chung, SH Lam, TP Lam, JF Chan, KH Chan, TC Wu, PL Ho, JW Chan, CS Lau, KK To, KY Yuen.

SARS-CoV-2 shedding and seroconversion among

passengers quarantined after disembarking a cruise ship: A case series.

The Lancet Infectious Diseases 2020 Sep;20(9):1051-1060.

DOI: 10.1016/S1473-3099(20)30364-9

 

79.321

DYH Yap, CH Tam, S Yung, S Wong, CSO Tang, TMY Mok, CKY Yuen, MKM Ma, CS Lau, TM Chan.

Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis.

Nephrology Dialysis and Transplantation 2020; 35: 810-818. DOI: 10.1093/ndt/gfy284

 

5.992

PH Li, ASY Leung, RMY Li, TF Leung, CS Lau, GWK Wong.

Increasing incidence of anaphylaxis in Hong Kong from 2009 to 2019-discrepancies of anaphylaxis care between adult and paediatric patients.

Clinical and Translational Allergy. 2020 Nov 19;10(1):51.

DOI: 10.1186/s13601-020-00355-6

 

5.871

SCW Chan, PH Li, KH Lee, HHL Tsang, CS Lau, HY Chung.

Diagnostic utility of whole spine and thoracic spine MRI corner inflammatory lesions in axial spondyloarthritis.

Therapeutic Advances in Musculoskeletal Disease. 2020 Nov 24;12:1759720X20973922.

PMID:33281954. DOI: 10.1177/1759720X20973922

 

5.346

TYM Leung, YLA Chan, EWY Chan, KY CHAN, SLC Chui, BJ Cowling, L GAO, M GE, FNI Hung, MSM Ip, P Ip, GKK Lau, CS Lau, KW Lau, WK Leung, X Li, H Luo, KKCM Man, WSV NG, DCW Siu, YFE Wan, YKW Wing, SCMW Wong, KHTW Wong and ICK Wong

Short- and potential long-term adverse health outcomes of COVID-19: A rapid review.

Emerging Microbes & Infections. 2020,9(1): 2190-2199.

http://dx.doi.org/10.1080/22221751.2020.1825914

 

5.842

JCY Wong, EYL Au, HHF Yeung, CS Lau, PH Li.

Piperacillin-tazobactam allergies: An exception to usual penicillin allergy.

Allergy, Asthma & Immunology Research 2021 Mar;13(2):284-294.

https://doi.org/10.4168/aair.2021.13.2.284

 

5.764

YF Wang, Y Zhang, Z Lin, H Zhang, TY Wang, Y Cao, DL Morris, Y Sheng, X Yin, SL Zhong, X Gu, Y Lei, J He, Q Wu, JJ Shen, J Yang, TH Lam, JH Lin, ZM Mai, M Guo, Y Tang, Y Chen, Q Song, B Ban, CC Mok, Y Cui, L Lu, N Shen, PC. Sham, CS Lau, DK Smith, TJ Vyse, X Zhang, YL Lau, W Yang.

Identification of 38 novel loci for systemic lupus erythematosus and genetic heterogeneity between ancestral groups.

Nature Communications 2021:12;772.

DOI: 10.1038/s41467-021-21049-y

 

14.92

SK Kwok, LM Tang, HL Tsang, HY Chung, MH Chung, CT Ho, CS Lau, TT Cheung.

Nurse-led consultations for patients with rheumatoid arthritis at low disease activity– a randomized non-inferiority trial.

Arthritis Care and Research (Hoboken) 2021 May 10. P

MID: 33973407. DOI: 10.1002/acr.24625

 

4.794

J Ma, IK Lam, CS Lau, VS Chan.

Elevated interleukin-18 receptor accessory protein mediates enhancement in reactive oxygen species production in neutrophils of systemic lupus erythematosus patients.

Cells. 2021 May;10(5):964.

DOI: https://doi.org/10.3390/cells10050964

 

6.600

R Kandane-Rathnayake, W Louthrenoo, SF Luo, YJJ Wu, YH Chen, V Golder, A Lateefm J Cho, SV Navarra, Leonid Zamora, L Hamijoyo, S Sockalingam, A Yuan, A Li, R Montes, S Oon, Y Katsumata, M Harigai, Y Hao, Z Zhang, M Chan, J Kikuchi, T Takeuchi, F Goldblatt, S O’Neill, SC Bae, CS Lau, A Hoi, CS Karyekar, M Nikpour, EF Morand, Asia-Pacific Lupus Collaboration.

Patterns of medication use in systemic lupus erythematosus – A multi-centre cohort study.

Arthritis Care and Research 2021 Jul 1.

DOI: 10.1002/acr.24740. PMID 34197023

 

4.794

SCW Chan, CK Teo, PH Li, KK Lau, CS Lau, HY Chung. Cardiovascular risk in patients with spondyloarthritis and association with anti-TNF drugs.

Therapeutic Advances in Musculoskeletal Disease 2021 Jul 27;13:1759720X211032444.

PMID:34377159. DOI: 10.1177/1759720X211032444

 

5.346

Q Lu, H Long, S Chow, S Hidayat, R Danarti, Y Listiawan, D Deng, Q Guo, H Fang, J Tao, M Zhao, L Xiang, N Che, F Li, H Zhao, CS Lau, FC Ip, KM Ho, AC Paliza, C Vicheth, K Godse, S Cho, CS Seow, Y Miyachi, TH Khang, R Ungpakorn, H Galadari, R Shah, K Yang, Y Zhou, C Selmi, AH Sawalha, X Zhang, Y Chen, CS Lin.

Guideline for the diagnosis, treatment and long-term management of cutaneous lupus erythematosus.

Journal of Autoimmunity 2021 Sep; 123:102707.

DOI: 10.1016/j.jaut.2021.102707. PMID: 34364171

 

7.094

R Kandane-Rathnayake, W Louthrenoo, V Golder, SF Luo, YJ Wu, A Lateef, J Cho, Z Li, Y An, L Hamijoyo, S Navarra, L Zamora, Y Katsumata, M Harigai, S Sockalingam, M Chan, YH Chen, S O'Neill, F Goldblatt, Y Hao, Z Zhang, J Kikuchi, T Takeuchi, CS Lau, M Nikpour, E Morand, A Hoi.

Asia Pacific Lupus Collaboration. Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: A longitudinal, multinational study. Rheumatology (Oxford). 2021 Nov 3;60(11):5185-5193.

DOI: 10.1093/rheumatology/keab217. PMID: 33693676

 

7.580

X Li, X Tong, WYW Yeung, K Peng, SHH Yum, SLC Chui, TTF Lai, YFE Wan, CKH Wong, EWY Chan, CS Lau. and ICK Wong

Two-dose Covid-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong.

Annals of the Rheumatic Diseases. 2021 http://dx.doi.org/10.1136/annrheumdis-2021-221571

 

19.103

KM Chow, C Ahn, I Dittmer, DK Au, I Cheung, YL Cheng, CS Lau, DTK Yeung, P Li.

Introducing incentives and reducing disincentives in enhancing deceased organ donation and transplantation

Special issue on Kidney donation and transplantation: Ethics and controversies.

Seminars in Nephrology (Accepted for publication)

 

5.299

LS Tam, J So, H So, VTL Wong, R Ho, TY Wu, P Wong, LHP Tam, C Ho, T L, YK Chung, WL Li, CH To, CS Lau, CC Mok.

Predictors of rapidly progressive interstitial lung disease and mortality in patients with autoantibodies against MDA5 dermatomyositis.

Rheumatology (Oxford) (Accepted for publication)

 

7.580

H So, J So, T Lam, VTL Wong, R Ho, WL Li, CS Lau, LS Tam.

Performance of the 2017 EULAR/ACR classification criteria in anti-MDA5 associated idiopathic inflammatory myopathy.

Arthritis and Rheumatology 2022 (Accepted for publication)

 

9.002




Grant Record
  1. The Nuffield Foundation – Oliver Bird Fund for Research into Rheumatism (1991)
    A study to investigate the mechanisms of thrombosis in patients with anti phospholipid syndrome
    (as principal investigator (£10,326)
  2. Scottish Hospital Endowments Research Trust (1991)
    The investigation of plasma fibrinolysis and the fibrinolytic potential of patients with rheumatoid vasculitis
    (as principal investigator) (£11,298)
  3. Committee on Research and Conference Grants, University of Hong Kong (1993)
    A study to investigate the monocyte bcl-2 proto-oncogene expression and the use of plasma factor VIII von Willebrand factor antigen measurement in monitoring disease progress in patients with system lupus erythematosus
    (as principal investigator) (HK$117,750)
  4. Committee on Research and Conference Grants, University of Hong Kong (1994)
    Cytokine receptor expression in systemic lupus erythematosus
    (as principal investigator) (HK$100,000)
  5. Committee on Research and Conference Grants, University of Hong Kong (1994)
    Development of a Western blot assay to study anti-ENA antibodies in patients with systemic lupus erythematosus
    (as co-investigator) (HK$60,000)
  6. Croucher Research Grants (1994)
    A study to investigate the pathogenetic role of CD5+ B-lymphocyte subset in systemic lupus erythematosus
    (as principal investigator) (HK$587,833)
  7. Committee on Research and Conference Grants, University of Hong Kong (1995)
    The use of anti-ribosomal protein antibodies, anti-neuronal antibodies and factor VIII von Willebrand factor antigen in the diagnosis and monitoring of major neurological manifestations of SLE
    (as principal investigator) (HK$116,000)
  8. Committee on Research and Conference Grants, University of Hong Kong (1995)
    The chemistry and biology of anti-rheumatic drugs bucillamine and D-penicillamine
    (as co-investigator) (HK$80,000)
  9. Committee on Research and Conference Grants, University of Hong Kong (1996)
    The study of genetic influence on disease susceptibility and severity in patients with rheumatoid arthritis in Hong Kong
    (as principal investigator) (HK$80,000)
  10. Earmarked Grant for Research, Research Grants Council (1996)
    Investigation of anti-rheumatic drugs: triptolide, bucillamine and their analogues
    (as principal investigator) (HK$692,000)
  11. Post-doctoral research fellowship grant for Dr KK Tong for 3 years, University of Hong Kong (1996)
    (as supervisor) (HK$828,000)
  12. Committee on Research and Conference Grants, University of Hong Kong (1997)
    he elucidation of the roles of regulatory suppressor T-lymphocytes in rheumatoid arthritis
    (as principal investigator) (HK 135,000)
  13. University of Hong Kong Teaching Development Grants (1997)
    stablishment of a computerised archival system for teaching materials
    (as co-principal investigator) (HK$246,300)
  14. Central Fund of Hong Kong Polytechnic University (1998)
    An evaluation of combined psychological treatment and occupational therapy in the management of patients with rheumatoid arthritis in Hong Kong
    (as co-investigator) (HK$110,000)
  15. Committee on Research and Conference Grants, University of Hong Kong (1998)
    The role of interleukin-15 in the pathogenesis of rheumatoid arthritis
    (as principal investigator) (HK$106,000)
  16. Health Services Promotion Fund (1999)
    Translation and validation of Arthritis Impact Measurement Scale-2 (AIMS-2) into Chinese
    (as co-principal investigator) (HK$$88,600)
  17. Committee on Research and Conference Grants, University of Hong Kong (1999)
    Elucidation of the mechanism of impaired mannose binding lectin production in systemic lupus erythematosus
    (as principal investigator) (HK$$88,600)
  18. Post-doctoral fellowship grant for Dr Y Ren for 2 years, University of Hong Kong (1999)
    (as supervisor) (HK$588,000)
  19. Vice-Chancellor's Development Fund on Chinese Medicine, School of Traditional Chinese Medicine, University of Hong Kong (1999)
    Elucidation of the effects of triptolide & its analogues on immunomodulatory cell & synovial fibroblast function in rheumatoid arthritis
    (as principal investigator) (HK$175,000)
  20. Merck Educational Grant (1999)
    A study of the socio-economic impact of rheumatoid arthritis and osteoarthritis and their treatment side-effects in Hong Kong
    (as principal investigator) (HK$76,000)
  21. Research Grants Council Earmarked Grant (1999)
    The role of adrenomedullin in inflammation
    (as co-investigator) (HK$763,200)
  22. Research Grants Council Earmarked Grant (1999)
    B cell apoptosis in systemic lupus erythematosus
    (as co-investigator) (HK$690,000)
  23. University Research Grants (2000)
    Towards a better understanding of the role of nitric oxide in the pathogenesis of systemic sclerosis
    (as principal investigator) (HK$120,000)
  24. University Research Grants (2001)
    A study to investigate the handling of apoptotic cells by phagocytes in systemic lupus erythematosus
    (as principal investigator) (HK$60,000)
  25. Earmarked Research Grant, Research Grants Council (2002)
    A randomised double-blind, placebo-controlled crossover clinical study of the efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sjögren’s syndrome
    (as co-investigator) (HK$423,010)
  26. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG) (2002)
    Effects of sex hormones on lymphocyte function in systemic lupus erythematosus
    (as principal investigator) (HK$87,900)
  27. Department of Medicine, University of Hong Kong (2002)
    Expression of cyclooxygenase iso-enzymes in the salivary gland of patients with primary Sjögren’s syndrome
    (as principal investigator) (HK$100,000)
  28. Vice-Chancellor’s SARS Research Fund, University of Hong Kong (2003)
    A study to evaluate the immunopathology of severe acute respiratory syndrome
    (as principal investigator) (HK$100,000)
  29. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG), University of Hong Kong (2003)
    Evaluation of the effects of sex hormones on neutrophils and macrophage apoptosis and macrophage phagocytic clearance of apoptotic neutrophils in systemic lupus erythematosus
    (as principal investigator) (HK$68,000)
  30. Earmarked Research Grant, Research Grants Council (2003)
    Complement deficiency and dendritic cell function in the pathogenesis of systemic lupus erythematosus
    (as principal investigator) (HK$939,968 + HK$50,000 University of Hong Kong Matching Grant = HK$989,968)
  31. Integrated Chinese Medicine Holdings (2003)
    Evaluation of the effects of Lingzhi and Huangqi on rheumatoid arthritis
    (as principal Investigator) (HK$265,166)
  32. Jannsen & Cilag Research Fund (2005)
    Socio-economic costs of rheumatoid arthritis in Hong Kong
    (as principal Investigator) (HK$50,000)
  33. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG), University of Hong Kong (2005)
    – Dendritic cell function and their effects on B cell activation in systemic lupus erythematosus
    (as principal investigator) (HK$66,150)
  34. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG), University of Hong Kong (2005)
    p21 gene polymorphism with systemic lupus erythematosus and rheumatoid arthritis
    (as co-investigator) (HK$ 66,150)
  35. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG), University of Hong Kong (2006)
    Association of B Lymphocyte Stimulator (BLyS) gene polymorphisms with systemic lupus erythematosus (SLE)
    (as co-investigator) (HK$70,000)
  36. Croucher Foundation Conference Organising Grant (2006)
    Asia Autoimmunity Forum
    (as Chairman of organising committee) (HK$76,000 + HK$28,500 HK SAR Government matching grant = HK$105,000)
  37. Aspreva Investigator Research Grant (2006)
    (as co-principal investigator) (US$100,000 + US$50,000 HK SAR Government matching grant = US$150,000)
  38. The Institute of Cardiovascular Research (2007)
    Pathogenesis of inflammatory autoimmune diseases
    (as principal investigator) (£25,000)
  39. Tenovus (2008)
    Early atherosclerosis in young patients with systemic lupus erythematosus: Utilization of a novel ex-vivo model of endothelial dysfunction
    (as co-principal investigator) (£10,000)
  40. Tenovus (2008)
    A multi-user Machine: the Randox RX Daytona clinical chemistry system
    (as co-investigator) (£10,000)
  41. Anonymous Trust (2008)
    Effects of high dose UVA1 phototherapy on cutaneous fibrosis and endothelial cell function in patients with systemic sclerosis
    (as co-principal investigator) (£9,900)
  42. Tenovus (2009)
    An investigation of the level of immune cell activity and its regulation in patients with systemic lupus erythematosus
    (as principal investigator) (£10,000)
  43. Lupus UK (2009)
    Lupus UK East of Scotland Nurse
    (as co-principal investigator) (£155,830)
  44. Seed Fund Scheme, Stem Cell and Regenerative Medicine Consortium (2010)
    Immunogenicity of hESC and iPSC-derived grafts using a humanized mouse model
    (as co-principal investigator) (~HK$716,410)
  45. Seed Funding Programme for Basic Research, University of Hong Kong (2010)
    Characterisation of the features and functional changes of bone marrow dendritic cells in systemic lupus erythematosus
    (as principal investigator) (HK$100,000)
  46. Seed Funding Programme for Basic Research, University of Hong Kong (2010)
    The effect of adrenomedullin on gene and protein expression in macrophages stimulated by tumour necrosis factor-alpha
    (as co-investigator) (HK$67,000)
  47. Educational Activities to set-up a Musculoskeletal Radioimaging Training centre in Queen Mary Hospital, Pfizer (2010)
    (HK$200,000)
  48. Educational Activities to set-up a Musculoskeletal Radioimaging Training centre in Queen Mary Hospital, Pfizer (2011)
    (HK$180,000)
  49. The Shun Tak District Min Yuen Tong of Hong Kong (2011-2013)
    Pathogenic studies of autoimmune rheumatic disease.
    (as principal investigator) (HK$1,500,000)
  50. General Research Fund (2011-2014)
    Functional characterization of the novel C-type lectin-like receptor CLEC16A and its expression association in systemic lupus erythematosus.
    (as co-investigator) (HK$980,000)
  51. Seed Funding Programme for Basic Research, University of Hong Kong (2012)
    Does adrenomedullin reduce the inflammatory response caused by advanced glycation endproducts?
    (as co-investigator) (HK$72,300)
  52. Seed Funding Programme for Basic Research, University of Hong Kong (2012)
    Interactions between plasmacytoid dendritic cells and T regulatory / interleukin-17 producing T-helper cells in systemic lupus erythematosus
    (as principal investigator) (HK$61,100)
  53. Small Project Funding Programme, Committee on Research and Conference Grants (CRCG), University of Hong Kong (2013)
    The role of plasmacytoid dendritic cells in systemic lupus erythematosus
    (as principal investigator) (HK$77,119)
  54. General Research Fund (GRF) (2013-2015)
    The role of regulatory microRNAs in plasmacytoid dendritic cell functions in systemic lupus erythematosus immunopathogenesis
    (as principal investigator) (HK$692,826)
  55. General Research Fund (GRF) (2013-2016)
    Relationship between matrix G1a protein and osteogenic endothelial progenitor cells with vascular and valvular calcification in patients with rheumatoid arthritis: Potential therapeutic role of vitamin K
    (as Co- investigator) (HK$649,524)
  56. Brian and Catherine Lau unrestricted grants.
    Improving the outcome of ankylosing spondylitis in Hong Kong (2014 – 2017) (HK$1,000,000)
  57. General Research Fund (GRF). (2014-2016)
    The role of IL-33 in the modulation of macrophage differentiation and immunoregulatory functions in systemic lupus erythematosus
    (as Co- investigator) (HK$866,032)
  58. University Grants Committee Funding Scheme for Teaching and Learning Related Proposal (2014-2017)
    Interprofessional Team-based Learning for Health Professional Students
    (as Co- investigator) (HK$5,069,000)
  59. Croucher Foundation (2014-2018)
    Advances in Immunology in Health and Disease (Croucher Summer Course 2014-2018)
    (as Summer Course Director) (HK$1,800,000)
  60. Health and Medical Research Fund (2015 – 2017)
    Validation of a new definition of lupus low disease activity state (LLDAS): Clinical and management implications
    (as principal investigator) (HK$476,120.00)
  61. Roche Investigator-initiated Study (2016 – 2019)
    A real world study comparing the efficacy and safety of tocilizumab in monotherapy and in combination with conventional synthetic disease modifying anti-rheumatic drugs
    (as principal investigator) (HK$642,369)
  62. University Grants Committee Funding Scheme for Teaching and Learning Related Proposals (2016 – 2019)
    Beyond the E-portfolio: Connectivity and Communities of Learning in a Virtual Environment
    (as Co-investigator of the project 2014 – 2017) (HK$5,699,225)
  63. University Grants Committee Theme-based Research Scheme
    Centre for Research into Circulating Fetal Nucleic Acids
    (as Co-principal investigator of the project 2016-2020) (HK$2,500,000 to HKU)
  64. General Research Fund (GRF) (2017-2020)
    Regulation of inflammasome activation in systemic lupus erythematosus
    (as Co-investigator of the project) (HK$1,229,089)
  65. Mr M Hui and Family Donation (2018)
    Drug allergy testing and desensitization
    (as Co-principal investigator) (HK$1,200,000)
  66. Health and Medical Research Fund (2019 – 2020)
    Dysregulation of interleukin-18 receptor accessory protein in neutrophils of lupus nephritis patients – a pilot study
    (as principal investigator of the project) (HK$100,000)
  67. Innovation and Technology Commission (ITC) (2020-2025)
    Health@InnoHK (ITC), Centre for Translational Stem Cell Biology (CTSCB)
    (as Co- principal investigator) (HK$ 284.6M)
  68. RGC Collaborative Research Fund COVID-19 and Novel Infectious Disease Exercise (Ref: C7154-20G) 2021-2024)
    A multinational big data Covid-19 Epidemiological Study on post-infection Outcomes (ACESO)
    (as Co- principal investigator) (HK$9,691,060)
  69. Health and Medical Research Fund Commissioned Grant (2021 – 2026)
    The long term spill-over impact of COVID-19 on health and healthcare of patients with non-communicable diseases: an in-depth outcome and health economic evaluation
    (as Co-investigator) (HK$9,334,600)
  70. Health and Medical Research Fund Commissioned Grant (2021 – 2024)
    COVID-19 vaccines adverse events response and evaluation (CARE) programme
    (as Co-investigator of the project (HK$10,000,000)

Key Offices
  • Dean, Li Ka Shing Faculty of Medicine, The University of Hong Kong
  • Immediate Past President, Hong Kong Academy of Medicine (2016-2020)
  • Immediate Past Chairperson, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong (2019-2022)
  • Immediate past Chief of Service, Department of Medicine, Queen Mary Hospital (2018-2022)
  • Past President, Asia-Pacific League of Associations for Rheumatology (2006-2008)